Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

If you're looking for web links only in Google Search results, create a custom search shortcut for your browser. Peter is a writer and editor for the CNET How-To team. He has been covering technology, ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Array allowed Samsung and T-Mobile deliver app recommendations and direct downloads to users. Researcher Ben Edelman claimed AppLovin’s code enabled automatic app installs through ads. AppLovin denied ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Until now, the early phase of drug discovery for the development of new therapeutics has been both cost- and time-intensive. Researchers at KIT (Karlsruhe Institute of Technology) have now developed a ...

Does Microsoft's search engine have what it takes to compete with the all-powerful Google? After testing Bing and Google side by side on basic search, news, shopping, AI features, and much more, we ...

St. Helens police face $243K overtime surge amid staffing shortages and child abuse cases The St. Helens Police Department is projected to spend nearly a quarter of a million dollars over budget for ...

The National Weather Service has issued winter storm warnings and winter weather advisories to run across the higher elevations of the Tug Hill region as widesp Oneida City School District to launch ...

Every week, the Array team reviews the latest news and analysis about the evolving field of eDiscovery to bring you the topics and trends you need to know. This week’s post covers the period of June 8 ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...